Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 20/20 | 0.60 |
| ▸ | CTSD | P07339 | 6/20 | 0.60 |
| ▸ | BACE2 | Q9Y5Z0 | 6/20 | 0.56 |
| ▸ | CTSE | P14091 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6043906 | 0.94 | BACE1 (0.64) | BACE1CTSDBACE2CTSE | |
| SCHEMBL6044248 | 0.87 | BACE1 (0.65) | BACE1CTSDBACE2 | |
| SCHEMBL6043487 | 0.87 | BACE1 (0.59) | BACE1CTSDBACE2CTSE | |
| SCHEMBL6044164 | 0.84 | BACE1 (0.61) | BACE1CTSDBACE2CTSE | |
| SCHEMBL6044118 | 0.82 | BACE1 (0.59) | BACE1CTSDBACE2 | |
| SCHEMBL6043685 | 0.82 | BACE1 (0.41) | BACE1CTSDBACE2CTSE | |
| SCHEMBL6043980 | 0.81 | BACE1 (0.62) | BACE1CTSDBACE2CTSE | |
| SCHEMBL6044289 | 0.80 | BACE1 (0.66) | BACE1CTSDBACE2CTSE | |
| SCHEMBL8364974 | 0.80 | BACE1 (0.78) | BACE1CTSDBACE2CTSE | |
| SCHEMBL6043796 | 0.79 | BACE1 (0.59) | BACE1CTSDBACE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060089355-A1 | Methods of treating alzheimer's disease using aromatically substituted w-amino-alkanoic acid amides and alkanoic acid diamides | ELAN PHARMACEUTICALS, INC. | 2006-04-27 | — | — | US | disclosed |
| US-20060079533-A1 | Methods of treating alzheimer's disease | NIEMAN JAMES A | 2006-04-13 | — | — | US | disclosed |
| WO-2002076440-A2 | METHODS OF TREATING ALZHEIMER'S DISEASE WITH PIPERIDIN DERIVATES | ELAN PHARMACEUTICALS, INC. (US) | 2002-10-03 | — | — | WO | disclosed |
| US-6051712-A | PREVENTION OF HIGH BLOOD PRESSURE AND CARDIAC INSUFFICIENCY, AS WELL AS GLAUCOMA, CARDIAC INFARCT, KIDNEY INSUFFICIENCY AND RESTENOSIS | HOFFMANN-LA ROCHE INC. (US) | 2000-04-18 | — | — | US | disclosed |
| US-5641778-A | EXHIBIT RENIN-INHIBITING PROPERTIES AND CAN BE USED AS ANTIHYPERTENSIVE AGENTS | CIBA-GEIGY CORPORATION (US) | 1997-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060089355-A1 | Methods of treating alzheimer's disease using aromatically substituted w-amino-alkanoic acid amides and alkanoic acid diamides | APP, BACE1, BACE2 | BACE1 2/4885CTSD 686/4885BACE2 3/4885 |
| US-20060079533-A1 | Methods of treating alzheimer's disease | BACE1, PSEN1, PSEN2 | BACE1 1/4885CTSD 92/4885BACE2 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.